Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
Identifieur interne : 000D84 ( Main/Exploration ); précédent : 000D83; suivant : 000D85Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
Auteurs : RBID : pubmed:22237846English descriptors
- KwdEn :
- Adult, Antibodies, Monoclonal (pharmacokinetics), Antibodies, Monoclonal (therapeutic use), Feasibility Studies, Female, Humans, Indium Radioisotopes (therapeutic use), Lymphoma, Non-Hodgkin (metabolism), Lymphoma, Non-Hodgkin (radiotherapy), Male, Radioimmunotherapy, Radiometry, Radiotherapy Dosage.
- MESH :
- chemical , pharmacokinetics : Antibodies, Monoclonal.
- chemical , therapeutic use : Antibodies, Monoclonal, Indium Radioisotopes.
- metabolism : Lymphoma, Non-Hodgkin.
- radiotherapy : Lymphoma, Non-Hodgkin.
- Adult, Feasibility Studies, Female, Humans, Male, Radioimmunotherapy, Radiometry, Radiotherapy Dosage.
Abstract
Radioimmunotherapy with (90)Y-ibritumomab tiuxetan has been used successfully used in the treatment of CD20-positive non-Hodgkin's lymphoma (NHL). Pretherapy imaging with (111)In-ibritumomab tiuxetan has been used in provisional dosimetry studies. Posttherapy imaging of (90)Y-ibritumomab tiuxetan for clinical use is appealing as it would simplify the data acquisition process and allow measurements of actual doses absorbed during treatment.
DOI: 10.1007/s00259-011-2040-5
PubMed: 22237846
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.</title><author><name sortKey="Arrichiello, C" uniqKey="Arrichiello C">C Arrichiello</name><affiliation wicri:level="1"><nlm:affiliation>Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G Pascale, Napoli, Italy. c.arrichiello@gmail.com</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G Pascale, Napoli</wicri:regionArea></affiliation></author><author><name sortKey="Aloj, L" uniqKey="Aloj L">L Aloj</name></author><author><name sortKey="Mormile, M" uniqKey="Mormile M">M Mormile</name></author><author><name sortKey="D Ambrosio, L" uniqKey="D Ambrosio L">L D'Ambrosio</name></author><author><name sortKey="Frigeri, F" uniqKey="Frigeri F">F Frigeri</name></author><author><name sortKey="Carac, C" uniqKey="Carac C">C Caracò</name></author><author><name sortKey="Arcamone, M" uniqKey="Arcamone M">M Arcamone</name></author><author><name sortKey="De Martinis, F" uniqKey="De Martinis F">F De Martinis</name></author><author><name sortKey="Pinto, A" uniqKey="Pinto A">A Pinto</name></author><author><name sortKey="Lastoria, S" uniqKey="Lastoria S">S Lastoria</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.1007/s00259-011-2040-5</idno><idno type="RBID">pubmed:22237846</idno><idno type="pmid">22237846</idno><idno type="wicri:Area/Main/Corpus">000F62</idno><idno type="wicri:Area/Main/Curation">000F62</idno><idno type="wicri:Area/Main/Exploration">000D84</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Monoclonal (pharmacokinetics)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Feasibility Studies</term><term>Female</term><term>Humans</term><term>Indium Radioisotopes (therapeutic use)</term><term>Lymphoma, Non-Hodgkin (metabolism)</term><term>Lymphoma, Non-Hodgkin (radiotherapy)</term><term>Male</term><term>Radioimmunotherapy</term><term>Radiometry</term><term>Radiotherapy Dosage</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Indium Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lymphoma, Non-Hodgkin</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Lymphoma, Non-Hodgkin</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Feasibility Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Radioimmunotherapy</term><term>Radiometry</term><term>Radiotherapy Dosage</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Radioimmunotherapy with (90)Y-ibritumomab tiuxetan has been used successfully used in the treatment of CD20-positive non-Hodgkin's lymphoma (NHL). Pretherapy imaging with (111)In-ibritumomab tiuxetan has been used in provisional dosimetry studies. Posttherapy imaging of (90)Y-ibritumomab tiuxetan for clinical use is appealing as it would simplify the data acquisition process and allow measurements of actual doses absorbed during treatment.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22237846</PMID><DateCreated><Year>2012</Year><Month>05</Month><Day>03</Day></DateCreated><DateCompleted><Year>2012</Year><Month>09</Month><Day>05</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1619-7089</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur. J. Nucl. Med. Mol. Imaging</ISOAbbreviation></Journal><ArticleTitle>Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.</ArticleTitle><Pagination><MedlinePgn>956-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-011-2040-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Radioimmunotherapy with (90)Y-ibritumomab tiuxetan has been used successfully used in the treatment of CD20-positive non-Hodgkin's lymphoma (NHL). Pretherapy imaging with (111)In-ibritumomab tiuxetan has been used in provisional dosimetry studies. Posttherapy imaging of (90)Y-ibritumomab tiuxetan for clinical use is appealing as it would simplify the data acquisition process and allow measurements of actual doses absorbed during treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study included 29 patients with non-Hodgkin's lymphoma, of whom 16 (group I) received a pretherapy (111)In-ibritumomab tiuxetan diagnostic study and (90)Y-ibritumomab tiuxetan treatment 1 week later, and 13 (group II) received only (90)Y-ibritumomab tiuxetan treatment. Planar imaging and blood sampling were performed in all patients. The doses absorbed by organs at risk were calculated using a whole-body average attenuation correction factor (relative dosimetry approach) and, in the case of the (111)In-ibritumomab tiuxetan image sets, also using organ-specific attenuation correction factors (absolute dosimetry method). Red marrow absorbed doses were based on gamma counting of blood samples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The estimated red marrow absorbed doses from (111)In and (90)Y data were equivalent. In all cases, the doses absorbed by organs at risk were found to be within prescribed limits. The relative dosimetry approach applied to both the (90)Y and (111)In data significantly underestimated the doses relative to those obtained with the (111)In absolute dosimetry method which is generally accepted as the reference method (MIRD 16). In the case of (111)In, the relative dosimetry approach values were highly correlated (R(2) = 0.61) with the reference method values. Relative dosimetry estimates may be adjusted multiplying by a correction factor of 2.8. The (90)Y-ibritumomab tiuxetan relative dosimetry data correlated poorly with the reference method values (R (2) = 0.02).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Based on patient-specific dosimetry, the administered activity may be increased by an average factor of 2.4, indicating that most patients could be undertreated. The relative dosimetry approach based on planar imaging largely underestimates doses relative to reference values. Dosimetry based on planar bremsstrahlung imaging is not a dependable alternative to (111)In dosimetry.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arrichiello</LastName><ForeName>C</ForeName><Initials>C</Initials><Affiliation>Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G Pascale, Napoli, Italy. c.arrichiello@gmail.com</Affiliation></Author><Author ValidYN="Y"><LastName>Aloj</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Mormile</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>D'Ambrosio</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Frigeri</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Caracò</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Arcamone</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>De Martinis</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lastoria</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>ibritumomab tiuxetan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lymphoma, Non-Hodgkin</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioimmunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiotherapy Dosage</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2012</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-011-2040-5</ArticleId><ArticleId IdType="pubmed">22237846</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D84 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D84 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22237846
|texte= Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22237846" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |